Trial of Retifanlimab With Trastuzumab and Pertuzumab Combination in HER2-Addicted Breast Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Clinical Trials Related to Pertuzumab
Related studies linked through entity extraction aliases.
Fulvestaciclib Combined With Anti-HER2 and Endocrine Therapy for HR+/HER2+ Advanced Breast Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
T-DXd Based Therapy Followed by Endocrine Therapy Plus Dual HER2 Blockade in First-line HER2+/ HR+ Metastatic Breast Cancer and Retreatment With T-DXd
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Roll-Over Study of Alpelisib (BYL719) for Continued Access and Long-Term Safety.
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Elacestrant in Advanced Triple Positive Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1/PHASE2
Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Phase II Study of Ultrasound and ctDNA Guided Neoadjuvant Systemic Therapy for Patients With HER2-positive Early Breast Cancer (UC HER Trial)
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study of JSKN003 Versus Trastuzumab in Combination With Pertuzumab and Docetaxel as First-Line Treatment for HER2-Positive Recurrent or Metastatic Breast Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study.
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
Optimization of Dynamic Neoadjuvant Therapy Strategies for HER2-Positive Breast Cancer Based on HER2-PET/CT Molecular Imaging
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE2
A Study of BL-M07D1 Combined With Pertuzumab Versus Docetaxel Plus Trastuzumab and Pertuzumab in Patients With First-line HER2-positive Recurrent or Metastatic Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Pyrotinib Combined With Trastuzumab and Pertuzumab for Maintenance Therapy in HER2-Positive Advanced Breast Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- N/A
A Phase III Study of KN026 in Combination With HB1801 as Adjuvant Therapy for Resectable HER2-Positive Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE3
De-escalation of Neoadjuvant Treatment (Paclitaxel + HP) in Early HER2+ Breast Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Ph2 Study for Optimization of Adjunct Systemic Therapy in HER2+ Patients, MolecularPCR Trial
- Status
- RECRUITING
- Phase
- PHASE2
Optimize Neoadjuvant Therapy in HER2-Positive Early-Stage Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE2
IBI354 With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive Metastatic Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE3
Trastuzumab Deruxtecan in First-Line HER2-Positive Metastatic Breast Cancer With Proactive Toxicity Management
- Status
- RECRUITING
- Phase
- PHASE2